Related Experiment Video

Updated: Jun 30, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Expression of SLAMF7 on hairy cell leukemia indicates therapy option with SLAMF7-antibody Elotuzumab

Anju Singh1, Mathis Bittermann1, Ibrahim Hammada1

  • 1Department of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany.

Leukemia Research Reports
|June 29, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Experiment Videos

Last Updated: Jun 30, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Articles linked to this work by shared authors, journal, and citation graph.

Genome-wide mapping and biophysical characterization of G-quadruplex structures in phytoplasma and their prospective role in host pathogenesis.

Physiology and molecular biology of plants : an international journal of functional plant biology·2026

Experience of a Single-Center Voriconazole TDM Bioassay for Hospitalized Patients with Invasive Fungal Infections.

Journal of pharmacy & bioallied sciences·2026

Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study.

Cancer control : journal of the Moffitt Cancer Center·2026

Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings.

International journal of cancer·2026

Targeting oxidative stress pathways in epilepsy: mechanistic insights into the role of ascorbic acid.

Molecular biology reports·2026

Effectiveness of Near Peer-Assisted Learning in Forensic Toxicology Teaching for Phase III MBBS Students: A Quasi-experimental, Pre-Test/Post-Test Study With Learner Perception Analysis.

Cureus·2026

Mixed phenotype acute leukemia: 13 patients and a proposed management algorithm.

Leukemia research reports·2026

Bilateral testicular infiltration as the initial presentation of NRAS-mutant juvenile myelomonocytic leukemia: rapid molecular remission following azacitidine and haploidentical stem cell transplantation.

Leukemia research reports·2026

Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy.

Leukemia research reports·2026

CD19-negative relapse with an apparent cytogenetic shift after blinatumomab-induced measurable residual disease clearance in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Leukemia research reports·2026

Synchronous presentation of pH+ B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia treated with blinatumomab.

Leukemia research reports·2026

Corrigendum to Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells [Leukemia Research Reports 25 (2026) 100570.1-1].

Leukemia research reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us